CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Beta Glucosylceramide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02126306
NCT02126306Phase 2Completed
CompareCT.gov

Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis

Hadassah Medical Organization·interventional·Posted Apr 30, 2014·Updated Oct 30, 2014

In Brief

A Phase 2 clinical trial evaluating Beta Glucosylceramide and Placebo for Compliance Behavior. Completed, enrolled 23 participants.

Detailed Summary

Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCompliance Behavior
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 30, 2014
Enrollment StartJan 1, 2006
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 12.2 years ago

Interventions

Beta Glucosylceramidedrug

Beta Glucosylceramide

Placebodrug

normal saline